Mr Forlenza and Mr Elkins will both report to Edward Ludwig, who will remain as chairman and CEO. John Considine will remain as vice chairman.
As president, Mr Forlenza will oversee Becton, Dickinson and Company’s (BD’s) three business segments (BD Medical, BD Diagnostics and BD Biosciences), International and the Quality function. He will continue to be a member of the Office of the CEO, along with vice chairman Mr Considine, executive vice presidents Gary Cohen, John Hanson and William Kozy, and Mr Elkins, who will join the Office of the CEO.
Mr Elkins will be responsible for executive management and oversight of BD’s global financial operations. He joins BD from AstraZeneca, where he has served since 2006 as vice president, CFO, North America and Global Marketing, a $13 billion business.
Mr Considine will continue to be responsible for integrated supply chain; information technology; environment, health and safety; project management and engineering services; and security.
Mr Ludwig said: “We are very pleased to welcome David as a member of our executive management team in this key role. He brings to BD a wealth of deep and diverse experience in global finance and healthcare. We look forward to leveraging his insight and expertise as we continue to implement our strategy of driving revenue growth through innovation, complemented by driving operating effectiveness and productivity.”